Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00246584 | A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US) | PHASE2 | COMPLETED | 300 | — | — | Oct 1, 2004 | - | Jul 28, 2006 | 1 | Switzerland |
| NCT00424541 | Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension | PHASE1 | COMPLETED | 34 | — | — | Jan 1, 2007 | Aug 1, 2007 | Dec 21, 2020 | 1 | Japan |
| Name | Type | Description |
|---|---|---|
| SPP100 | DRUG | - |
| SPP100 (aliskiren) | DRUG | - |
Inclusion Criteria: * Diagnosed as essential hypertension - Exclusion Criteria: * Patients with secondary hypertension or suspected of having secondary hypertension. * Patients suspected of having malignant hypertension * Patients with any serious diseases or symptoms